| Literature DB >> 34948281 |
Sofia Barbosa-Gouveia1,2, Maria E Vázquez-Mosquera1,2, Emiliano Gonzalez-Vioque3, Álvaro Hermida-Ameijeiras1,2, Laura L Valverde1,2, Judith Armstrong-Moron4,5, Maria Del Carmen Fons-Estupiña5,6, Liesbeth T Wintjes7, Antonia Kappen7, Richard J Rodenburg8, Maria L Couce1,2.
Abstract
Mitochondrial functional integrity depends on protein and lipid homeostasis in the mitochondrial membranes and disturbances in their accumulation can cause disease. AGK, a mitochondrial acylglycerol kinase, is not only involved in lipid signaling but is also a component of the TIM22 complex in the inner mitochondrial membrane, which mediates the import of a subset of membrane proteins. AGK mutations can alter both phospholipid metabolism and mitochondrial protein biogenesis, contributing to the pathogenesis of Sengers syndrome. We describe the case of an infant carrying a novel homozygous AGK variant, c.518+1G>A, who was born with congenital cataracts, pielic ectasia, critical congenital dilated myocardiopathy, and hyperlactacidemia and died 20 h after birth. Using the patient's DNA, we performed targeted sequencing of 314 nuclear genes encoding respiratory chain complex subunits and proteins implicated in mitochondrial oxidative phosphorylation (OXPHOS). A decrease of 96-bp in the length of the AGK cDNA sequence was detected. Decreases in the oxygen consumption rate (OCR) and the OCR:ECAR (extracellular acidification rate) ratio in the patient's fibroblasts indicated reduced electron flow through the respiratory chain, and spectrophotometry revealed decreased activity of OXPHOS complexes I and V. We demonstrate a clear defect in mitochondrial function in the patient's fibroblasts and describe the possible molecular mechanism underlying the pathogenicity of this novel AGK variant. Experimental validation using in vitro analysis allowed an accurate characterization of the disease-causing variant.Entities:
Keywords: Sengers syndrome; acylglycerol kinase; mitochondrial ATP generation; mitochondrial dysfunction; oxidative phosphorylation machinery
Mesh:
Substances:
Year: 2021 PMID: 34948281 PMCID: PMC8708263 DOI: 10.3390/ijms222413484
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Genetic analysis findings. (A) Genomic DNA sequence chromatograms showing Sanger sequencing results. Both parents carried the splicing variant c.518+1G>A, located in intron 8. (B) AGK gene: predicted effect of exon 9 skipping during mature mRNA splicing. (C) cDNA sequencing of patient [P] and control [C], showing a 96-bp decrease in the length of the AGK cDNA sequence.
Figure 2Representation of AGK protein domains. (A) Domain structure of AGK, which contains a two-domain fold (DGK domains 1 and 2) that mediates phosphorylation of monoacylglycerols or diacylglycerols, an N-terminal α1 helix (light blue) that anchors to the membrane, and a C-terminal region with an additional membrane anchor (light brown) helix loop. Schematic depicts the c.518+1G>A variant in the catalytic domain. (B) Protein modeling of wild-type AGK and of the AGK variant c.518+1G>A, showing predicted changes in spatial protein structure (red arrows).
Figure 3Seahorse XF96 respirometry analysis. (A) Oxygen consumption rate measured before and after the addition of inhibitors. These modulators are electron transport chain inhibitors (oligomycin, FCCP, and a mixture of rotenone and antimycin A), which are serially injected to measure ATP production, Max Resp, Non-Mito Resp, proton leak, SRC, and Basal Resp. (B) The basal energy metabolism of each cell line was assessed by determining OCR:ECAR ratios following sequential injection of the inhibitors. Abbreviations: Basal Resp, basal respiration; ECAR, extracellular acidification rate; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; Max Resp, maximal respiration; Non-Mito Resp, non-mitochondrial respiration; OCR, oxygen consumption rate; SRC, spare respiratory capacity. All data were obtained from two independent experiments, expressed as mean value ± deviation standard.
Measurement of enzyme activities for the different OXPHOS complexes in patient and control fibroblasts (reference range determined for healthy population).
| Patient-Activity (mU/U CS) | Control-Activity (mU/U CS) | Reference Range | |
|---|---|---|---|
|
|
|
|
|
| Complex II | 367 | 582 | 335–888 |
| Complex III | 592 | 628 | 570–1383 |
| Complex IV | 556 | 527 | 288–954 |
|
|
|
|
|
Bold font indicates complex for which reduced activity was observed. Abbreviations: CS, citrate synthase.